# Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

> **NCT00847301** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 472 (actual)

## Conditions studied

- Arthroplasty, Replacement
- Thromboembolism

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00847301
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 472 (ACTUAL)
- **Last updated:** 2015-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00847301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00847301, "Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT00847301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*